GSK abandons Alector after back-to-back neuro stumbles

PartnershipnegativeNegative

AI Analysis

Summary

GSK has abandoned its partnership with Alector after both antibody assets for neurodegenerative diseases failed to demonstrate significant clinical benefit in development.

Outcome Details

GSK abandons partnership with Alector; both antibody assets failed to show significant clinical benefit

Importance:7/10

Sentiment:

-0.90

partnership terminationclinical failureneurodegenerative diseaseantibody

Related Companies

$GSK $ALEC

Read the original article

Published by BioSpace on July 9, 2026 10:47 AM

Read Original